Perrigo Drug's Pricing Way Off, Expert Says In $163M Tax Trial

Law360 (June 7, 2021, 7:55 PM EDT) -- The $466 million an Israeli subsidiary of Irish drugmaker Perrigo Co. earned from sales of a heartburn medication "in no way can possibly comply" with transfer pricing law, an economist said Monday during the company's $163 million tax trial.

Drugmaker Perrigo is in a battle with the government over taxes on income earned by the company's Israeli subsidiary through sales of over-the-counter heartburn drug omeprazole. (AP Photo/James Prichard) Whether the drug's price was inflated was the crux of expert witness testimony on the last day of L. Perrigo Co.'s trial in Michigan federal court, which lasted nearly two weeks. The U.S. government has claimed that the subsidiary, Perrigo...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!